Alpha Tau Medical Ltd. - Form 20-F Summary (Fiscal Year Ended December 31, 2025)
Business Context and Reporting Period
Company: Alpha Tau Medical Ltd. (Nasdaq: DRTS)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Alpha Tau is a clinical-stage oncology therapeutics company developing the Alpha DaRT® (Diffusing Alpha-emitters Radiation Therapy) technology. This proprietary system utilizes Radium-224 to deliver localized alpha radiation for the treatment of solid tumors. The company has no commercial product revenue to date and is focused on advancing clinical trials for indications including squamous cell carcinoma (SCC), pancreatic cancer, glioblastoma, and prostate cancer.
Regulatory Status: The company holds marketing approval in Israel (2020) and received "shonin" pre-market approval in Japan (February 2026) for head and neck cancer. It is pursuing FDA approval via a PMA pathway for recurrent cutaneous SCC.
Key Financial Metrics
| Metric (in thousands USD) | 2024 | 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(31,750) | $(42,627) |
| Accumulated Deficit | $(147,509) | $(190,136) |
| Cash, Cash Equivalents & Deposits | $62,855 | $76,903 |
| Operating Expenses (Total) | $36,042 | $42,288 |
| Research & Development (Net) | $27,020 | $32,065 |
| General & Administrative | $6,673 | $8,363 |
| Marketing Expenses | $2,349 | $1,860 |
| Financial (Income) Expenses, Net | $(4,298) | $218 |
Note: All financial figures are in thousands of U.S. dollars unless otherwise noted. The company has no debt other than a long-term loan of approximately $6.35 million secured by deposits.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by 34.3% to $42.6 million in 2025, driven primarily by higher R&D expenses and a shift from financial income to financial expense.
- R&D Growth: R&D expenses rose 18.7% to $32.1 million due to increased employee compensation, raw material costs, and third-party contractor fees for expanding clinical trials.
- Capital Raises: The company raised approximately $45.5 million in net proceeds from equity issuances in 2025, including a registered direct offering with Oramed Ltd. ($36.8 million) and a subsequent private placement ($8.7 million).
- Financial Income Shift: Financial income of $4.3 million in 2024 turned into a net expense of $0.2 million in 2025. This was caused by a decrease in interest income and warrant remeasurement gains, offset by foreign exchange losses and warrant liability increases.
- Liquidity: Total cash and deposits increased to $76.9 million, providing a runway of at least two years for operations.
Guidance, Outlook, and Risks
Outlook and Milestones:
- ReSTART Trial: The pivotal U.S. trial for recurrent cutaneous SCC is expected to complete recruitment in Q1 2026, with top-line results anticipated in H2 2026 for potential FDA submission.
- Pancreatic Cancer: The IMPACT trial (Alpha DaRT + chemotherapy) began patient treatment in September 2025, with initial results expected in H2 2026.
- Japan Commercialization: Following pre-market approval in February 2026, the company entered a commercial agreement with HekaBio K.K. to distribute Alpha DaRT in Japan, subject to a post-market surveillance study.
- Manufacturing: The first phase of the Hudson, NH manufacturing facility is complete and licensed, with production expected to commence in 2026.
- Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require substantial additional funding to complete clinical trials and commercialize.
- Regulatory Uncertainty: Success depends on obtaining FDA PMA approval and similar authorizations globally. Delays or rejections would materially harm the business.
- Supply Chain: Reliance on a limited number of suppliers for Thorium-228 (the key input for Radium-224) poses a supply risk.
- Geopolitical Risk: Operations are heavily concentrated in Israel, exposing the company to regional instability, potential military call-ups, and supply chain disruptions.
- PFIC Status: The company believes it was a Passive Foreign Investment Company (PFIC) in 2025, which may have adverse tax consequences for U.S. shareholders.
Investor Verification Checklist
- Cash Runway: Verify the $76.9 million cash balance against the projected burn rate to confirm the "at least two years" liquidity estimate.
- Clinical Trial Enrollment: Monitor the recruitment status of the ReSTART (SCC) and IMPACT (Pancreatic) trials to ensure they meet the H2 2026 data readout timelines.
- Japan PMS Study: Confirm the initiation and enrollment progress of the required 66-patient post-market surveillance study in Japan.
- Supply Chain Security: Assess the status of Thorium-228 supply agreements and the operational readiness of the Hudson, NH facility.
- Equity Dilution: Review the impact of outstanding warrants (approx. 19 million) and options (approx. 16.7 million) on potential future dilution.